Assembly Biosciences Stock Forecast, Price & News

-0.07 (-1.96 %)
(As of 07/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume50,088 shs
Average Volume1.20 million shs
Market Capitalization$140.55 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Assembly Biosciences logo

About Assembly Biosciences

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.58 out of 5 stars

Medical Sector

985th out of 4,434 stocks

Pharmaceutical Preparations Industry

477th out of 1,734 stocks

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

Is Assembly Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Assembly Biosciences stock.
View analyst ratings for Assembly Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Assembly Biosciences?

Wall Street analysts have given Assembly Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Assembly Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Assembly Biosciences

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.10. Assembly Biosciences had a negative net margin of 78.57% and a negative trailing twelve-month return on equity of 24.46%.
View Assembly Biosciences' earnings history

How has Assembly Biosciences' stock been impacted by COVID-19?

Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ASMB stock has decreased by 77.6% and is now trading at $3.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ASMB?

5 Wall Street analysts have issued 1 year price targets for Assembly Biosciences' stock. Their forecasts range from $7.00 to $15.00. On average, they expect Assembly Biosciences' share price to reach $11.25 in the next year. This suggests a possible upside of 221.4% from the stock's current price.
View analysts' price targets for Assembly Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the following people:
  • Dr. John G. McHutchison A.O., M.D., FRACP, CEO, Pres & Director (Age 63, Pay $1.44M)
  • Dr. William E. Delaney IV, Ph.D., Chief Scientific Officer (Age 49, Pay $450.87k)
  • Mr. Jason A. Okazaki, Chief Legal & Bus. Officer and Corp. Sec. (Age 45, Pay $703.27k)
  • Dr. Uri A. Lopatin, Co-Founder and Clinical & Scientific Advisor (Age 49)
  • Dr. Adam Zlotnick, Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
  • Mr. Michael P. Samar, Sr. VP of Fin. & Bus. Operations and Principal Financial & Accounting Officer (Age 49)
  • Ms. Lauren Glaser, Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Jennifer A. Troia MHROD, SPHR, SHRM-SCP, Sr. VP of HR and Organization Devel.
  • Dr. Richard J. Colonno, Sr. Advisor (Age 71)
  • Dr. Tharaknath Rao, Head of Microbiome Clinical Devel. & Sr. VP

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

5 employees have rated Assembly Biosciences CEO John McHutchison on John McHutchison has an approval rating of 80% among Assembly Biosciences' employees.

Who are some of Assembly Biosciences' key competitors?

What other stocks do shareholders of Assembly Biosciences own?

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Marquette Asset Management LLC (0.06%). Company insiders that own Assembly Biosciences stock include Jacqueline Sybil Papkoff, Luisa M Stamm, Richard James Colonno, Timothy A Springer and William E Iv Delaney.
View institutional ownership trends for Assembly Biosciences

Which institutional investors are buying Assembly Biosciences stock?

ASMB stock was purchased by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC.
View insider buying and selling activity for Assembly Biosciences
or or view top insider-buying stocks.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $3.50.

How much money does Assembly Biosciences make?

Assembly Biosciences has a market capitalization of $140.55 million and generates $79.11 million in revenue each year. The biopharmaceutical company earns $-62,150,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

How many employees does Assembly Biosciences have?

Assembly Biosciences employs 139 workers across the globe.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is

Where are Assembly Biosciences' headquarters?

Assembly Biosciences is headquartered at 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 833-509-4583 or via email at [email protected]

This page was last updated on 7/26/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.